Home > Drug Search >
  • Targets: FMS-like tyrosine kinase 3 (FLT-3)
  •   > 
Drug Filter
Category:
chemistry (65) biology (1)
Status:
Approved (10) NDA Filing (2) Phase Ⅲ (10) Phase Ⅱ (20) Phase Ⅰ (24)
Clinical Stage:
Pending (5) Active (32) Discontinued (19)
Company:
Concert (1) CTI BioPharma (2) Daiichi Sankyo (3) Eisai (1) Enanta Pharmaceuticals (1) Exelixis (2) FGK Representative Service GmbH (1) Genzyme (1) Gilead (2) GlaxoSmithKline (1) Jiangsu Hengrui Medicine (1) Hutchison Medipharma (1) Intercept Pharmaceuticals (2) Johnson & Johnson (1) Kyowa Hakko Kirin (2) Lilly (2) Merck Serono (1) Merck Sharp & Dohme (3) National Cancer Institute (1) Novartis (4) Onyx Pharmaceutical (2) Otsuka (1) Pfizer (4) PTC Therapeutics (1) Roche (1) Sanofi (1) Sunesis Pharmaceuticals (1) Takeda (3) Vertex (3) Phenex (1) Cadila (1) Central Drug Research Institute (1) Unknown (1) Qilu Pharmaceutical (1) S*BIO (3) Astex Pharmaceuticals (2) 4SC AG (1) AROG Pharmaceuticals (1) Rigel (1) GliaCure (1) Celldex (1) vTv Therapeutics (1) Antisoma (1) QuintilesIMS (1) Zelgen Biosciences (1) HEC Pharm (1) Qilu Antibiotics (Linyi) Pharmaceutical (1) Sichuan University (1) Strategia Therapeutics (1) Symphony Evolution (1) Tragara (1) FLX Bio (1) ProQinase (1) Akinion (1) China Shijiazhuang Pharmaceutical Group/CSPC (1) Tufts University (1) University of Bradford (1) Abbott (1) Amgen (2) Ariad (2) Astellas (1) Baxter (1) Bayer (1) Boehringer Ingelheim (1) BTG plc (1) Celgene (1) Cell Therapies (1) Cephalon (1)
Indication:
Acute lymphoblastic leukaemia (ALL) (3) Acute myeloid Leukemia (AML) (16) Advanced renal cell carcinoma (RCC) (2) Alzheimer's disease (AD) (1) Breast cancer (3) Hypothyroidism (1) Chronic lymphocytic leukemia (CLL) (2) Chronic myeloid leukemia (CML ) (1) Pigmented villonodular synovitis (1) Anaplastic lymphoma kinase (ALK)-positive NSCLC (1) Spinocerebellar degeneration (1) Differentiated thyroid cancer (1) Dyslipidemia (1) Essential thrombocythaemia (ET) (1) Follicular lymphoma (1) Gastrointestinal stromal tumors (GISTs) (3) Hepatocellular carcinoma (HCC) (2) Hyperlipidemia (2) Idiopathic pulmonary fibrosis (IPF) (1) Idiopathic thrombocytopenic purpura (ITP) (1) Leukemia (2) Lung cancer (1) Lymphoma (1) Malignancies (1) Mantle cell lymphoma (MCL) (1) Melanoma (2) Multiple myeloma (MM) (2) Multiple sclerosis (MS) (1) Myelodysplastic syndrome (MDS) (1) Myelofibrosis (2) Non small cell lung cancer (NSCLC) (3) Non-alcoholic fatty liver disease (NAFLD) (4) Non-Hodgkin’s lymphoma (NHL) (1) Ovarian cancer (1) Pancreatic cancer (1) Postmenopausal osteoporosis (1) Primary biliary cirrhosis (PBC) (2) Prostate cancer (3) Psoriasis (1) Psoriatic arthritis (1) Renal cell carcinoma (5) Rheumatoid arthritis (RA) (3) Small cell lung cancer (SCLC) (1) Small lymphocytic lymphoma (SLL) (1) Solid tumours (15) Systemic lupus erythematosus (1) Colorectal cancer (2) Peroxisomal disorders (PD) (1) Inborn errors in primary bile acid synthesis (1) Aggressive systemic mastocytosis (ASM) (1) Systemic mastocytosis with associated hematological neoplasm (1) Mast cell leukemia (1) T-cell lymphoblastic lymphoma (1) Unresectable hepatocellular carcinoma (1) Metastatic non-small cell lung cancer (1) Anaplastic astrocytoma (1) Pancreatic neuroendocrine tumors (pNET) (1) B-cell lymphoma (1) Renal carcinoma (1) Hematological cancer (2) Tenosynovial giant cell tumor (TGCT) (1) Spinal muscular atrophy (2) Autoimmune diseases (1) Glioblastoma (1) Hepatic fibrosis (1) Chronic myelomonocytic leukemia(CMML) (1) Diffuse large B cell lymphoma (1) Liver cancer (1) Metabolic Syndrome X (1) Inflammation (1) Allergic diseases (1) Immune thrombocytopenic purpura (1)
Country:
Aprv. Year:
2006 (1) 2012 (1) 2013 (1) 2014 (1) 2016 (1) 2017 (2)
Others:
Sort: Aprv. Year Alphabetical Prev Next
First Prev 1 2 3 4 Next Last GO
Recently Viewed Drugs:
Insert title here
Feed-Back To Top
ICP Permit 14047345| Beijing PSB Hai Dian Record 11010802017043 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)
Insert title here
Feed-Back To Top